Skip to main content
. 2021 Jul 20;13(7):1098. doi: 10.3390/pharmaceutics13071098

Figure 10.

Figure 10

Growth inhibition of (A) MCF-7, (B) CAL-51 human breast cancer cell lines treated with different concentrations (1.25, 2.5, 5, and 10 μg mL−1) of TAM/RES–LbL-LCNPs. IC50 value for MCF-7 was 6.13 μg mL−1 and CAL-51was 4.62 μg mL−1, and (C) WRL-68 normal human liver cell line.